Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.63 |
| ▸ | HTR3B | O95264 | 1/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | HTR3A | P46098 | 1/20 | 0.63 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.63 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27361164 | 0.87 | PKM (0.79) | HTR6TSHRPKMALDH1A1LMNA | |
| SCHEMBL3826873 | 0.85 | HTR6 (1.00) | HTR6HTR3EHTR3BADRB1HTR3A | |
| SCHEMBL18553733 | 0.85 | HTR6 (0.73) | HTR6ALDH1A1KDM4ELMNAHTR3E | |
| SCHEMBL18553773 | 0.85 | HTR6 (0.73) | HTR6TSHRPKMALDH1A1KDM4E | |
| SCHEMBL3322151 | 0.82 | HTR6 (0.68) | HTR6 | |
| SCHEMBL31531621 | 0.80 | ALDH1A1 (0.71) | HTR6TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL18553766 | 0.80 | HTR6 (1.00) | HTR6PKMALDH1A1KDM4ELMNA | |
| SCHEMBL18553746 | 0.80 | HTR6 (0.89) | HTR6PKMALDH1A1KDM4ELMNA | |
| SCHEMBL18553730 | 0.79 | HTR6 (0.72) | HTR6 | |
| SCHEMBL20485034 | 0.79 | HTR6 (0.72) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2022-02-17 | — | — | US | disclosed |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200253958-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2020-08-13 | — | — | US | disclosed |
| US-10568882-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180250291-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2018-09-06 | — | — | US | disclosed |
| EP-3337788-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | Portola Pharmaceuticals, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017034997-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253958-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PCSK9, LDLR, PCSK7 | HTR6 2238/4885TSHR 1591/4885PKM 418/4885 |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PCSK9, LDLR, PCSK7 | HTR6 2238/4885TSHR 1591/4885PKM 418/4885 |
| US-20180250291-A1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | PCSK9, LDLR, APOB | HTR6 2326/4885TSHR 2083/4885PKM 215/4885 |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | HTR6 2238/4885TSHR 1591/4885PKM 418/4885 |
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | HTR6 2238/4885TSHR 1591/4885PKM 418/4885 |
| US-10568882-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | HTR6 2238/4885TSHR 1591/4885PKM 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.